April 24th 2024
Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Rheumatologists Still Leery of Biosimilar Use, Study Says
June 30th 2020In surveys conducted in February and March 2020, rheumatologists cited low adoption rates of biosimilars by payers and unfavorable discounts as major reasons why they feel uncomfortable switching prescribing patterns from reference products to biosimilars.
Doctors Manage Insulin Degludec-to-Glargine Transition Poorly, ADA Study Says
June 20th 2020There is much inconsistency in the way physicians transition patients from insulin degludec to insulin glargine upon hospital admission, leading to higher risk especially for patients with type 1 diabetes, according to a study presented at the American Diabetes Association 80th Scientific Sessions online conference.
Rising Costs Explain Why Canada Is Switching to Biosimilars
June 15th 2020Following in the footsteps of British Columbia, other Canadian provinces are working to implement their own biosimilars initiatives that would switch patients from some of the most costly reference biologics to biosimilar counterparts.
Part 1: NCCN Panel Discusses Patient Education on Biosimilars
May 22nd 2020Patient preferences play a large role in the effort to get biosimilars into the mainstream of therapeutics, and education is often a struggle, panelists said at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Annual Conference.
ISPOR Panelists Weigh the Success of APMs
May 19th 2020The alternative payment model (APM) doesn’t perfectly balance the competing interests of revenue growth and value-based care, but it has been a learning tool, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Panelists Advocate for Global Collaboration in RWE Effort
May 19th 2020Harmonized efforts across global borders and among stakeholders are needed to generate and build acceptance of real world evidence (RWE) to actively aid in health care decision making, panelists said at Virtual ISPOR 2020, the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research.
Surya Singh, MD, Explains How Biosimilar Education Has Reduced Provider Doubt
April 15th 2020Surya Singh, MD discusses how education efforts have reduced providers’ doubts surrounding the similarity between biosimilars and their reference products at the March 2020 FDA/Federal Trade Commission workshop on anticompetitive practices.